Statistics

Total Visits

Views
A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. 12

Total Visits per Month

March 2019 April 2019 May 2019 June 2019 July 2019 August 2019 September 2019
A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. 0 0 0 0 11 1 0

File Downloads

Views
A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy.pdf 4

Top Country Views

Views
Canada 4
South Korea 2
United States 2
China 1
Czech Republic 1
Sweden 1

Top City Views

Views
London 3
Memphis 2
Calgary 1
Dongguan 1
Nynäs 1